These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10370642)

  • 81. [Anti-ischemic effects of SIN-1, a molsidomine metabolite, during coronary angioplasty and antiplatelet effects in humans].
    Darius H; Erbel E; Schmucker B; Reusch U; Meyer J
    Presse Med; 1988 May; 17(20):1033-6. PubMed ID: 2969099
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Clinical pharmacokinetics of molsidomine.
    Rosenkranz B; Winkelmann BR; Parnham MJ
    Clin Pharmacokinet; 1996 May; 30(5):372-84. PubMed ID: 8743336
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Relationship between lower esophageal sphincter pressure and serum gastrin concentration in the newborn infant.
    Moroz SP; Beiko P
    J Pediatr; 1981 Nov; 99(5):725-8. PubMed ID: 7299545
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Somatostatin effects on lower esophageal sphincter function.
    Bybee DE; Brown FC; Georges LP; Castell DO; McGuigan JE
    Am J Physiol; 1979 Jul; 237(1):E77-81. PubMed ID: 111562
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Pharmacokinetics of molsidomine and its active metabolite, linsidomine, in patients with liver cirrhosis.
    Spreux-Varoquaux O; Doll J; Dutot C; Grandjean N; Cordonnier P; Pays M; Andrieu J; Advenier C
    Br J Clin Pharmacol; 1991 Sep; 32(3):399-401. PubMed ID: 1777378
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Neurotensin-related regulation of the postprandial lower-oesophageal-sphincter pressure.
    Horstmann O; Nustede R; Neufang T; Lepsien G; Becker H
    Langenbecks Arch Surg; 1999 Oct; 384(5):467-72. PubMed ID: 10552293
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Photoactivation of the nitric oxide donor SIN-1.
    Ullrich T; Oberle S; Abate A; Schröder H
    FEBS Lett; 1997 Apr; 406(1-2):66-8. PubMed ID: 9109387
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Relationship of serum gastrin response to lower oesophageal sphincter pressure.
    Dent J; Hansky J
    Gut; 1976 Feb; 17(2):144-6. PubMed ID: 1261885
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Release of plasminogen activator by molsidomine and its active metabolite SIN-1.
    Klöcking HP; Hoffmann A; Markwardt F
    Pharmazie; 1987 May; 42(5):354. PubMed ID: 3671454
    [No Abstract]   [Full Text] [Related]  

  • 90. Oxidative/Nitrative Mechanism of Molsidomine Mitotoxicity Assayed by the Cytochrome c Reaction with SIN-1 in Models of Biological Membranes.
    Paes de Barros M; Casares Araujo-Chaves J; Marlise Mendes Brito A; Lourenço Nantes-Cardoso I
    Chem Res Toxicol; 2020 Nov; 33(11):2775-2784. PubMed ID: 32706246
    [TBL] [Abstract][Full Text] [Related]  

  • 91. An impurity present in some samples of SIN-1 oxidizes it to nitric oxide in anaerobic solutions.
    Wang Y; Rochelle LG; Kruszyna H; Kruszyna R; Smith RP; Wilcox DE
    Toxicology; 1994 Mar; 88(1-3):165-76. PubMed ID: 8160198
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [Release of plasminogen activator by SIN-1].
    Kloecking HP; Hoffmann A; Markwardt F
    Pathol Biol (Paris); 1987 Feb; 35(2 Pt 2):231-2. PubMed ID: 3104866
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Dynamics of Irreversible NO Release from Photoexcited Molsidomine.
    Yoon H; Park S; Lim M
    J Phys Chem Lett; 2023 Jan; 14(2):516-523. PubMed ID: 36626829
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [Molsidomine (Corvaton)].
    Eliseev OM
    Ter Arkh; 1994; 66(9):82-8. PubMed ID: 7992225
    [No Abstract]   [Full Text] [Related]  

  • 95. The design of membrane-controlled transdermal therapeutic systems containing molsidomine.
    Yamada M; Tanigawara Y
    Chem Pharm Bull (Tokyo); 1987 Aug; 35(8):3407-12. PubMed ID: 3427719
    [No Abstract]   [Full Text] [Related]  

  • 96. [New aspects of the mechanism of action of molsidomine. Proceedings of a discussion by cardiology experts. Berlin, 15 April 1989].
    Med Klin (Munich); 1990 Feb; 85 Suppl 1():3-26. PubMed ID: 2333059
    [No Abstract]   [Full Text] [Related]  

  • 97. Prediction of the lower esophageal sphincter pressure after oral molsidomine by sydnonimine plasma concentrations.
    Stoschus B; Fernandez I; Heller J; Neubrand M; Sauerbruch T
    Hepatogastroenterology; 1999; 46(26):933-7. PubMed ID: 10370642
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Double blind placebo controlled study on the effect of the nitric oxide donor molsidomin and the 5-HT3 antagonist ondansetron on human esophageal motility.
    Willis S; Allescher HD; Stoschus B; Schusdziarra V; Classen M; Schumpelick V
    Z Gastroenterol; 1994 Nov; 32(11):632-6. PubMed ID: 7886971
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Effects of dexmedetomidine and propofol on lower esophageal sphincter and gastroesophageal pressure gradient in healthy volunteers.
    Turan A; Wo J; Kasuya Y; Govinda R; Akça O; Dalton JE; Sessler DI; Rauch S
    Anesthesiology; 2010 Jan; 112(1):19-24. PubMed ID: 20032699
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Effect of rioprostil, an oral prostaglandin E1 (PGE1) analogue, on lower esophageal sphincter pressure and on the motility of the distal esophagus in healthy volunteers.
    Baunack AR; Froese G; Demol P; Wargenau M; Ruoff HJ; Weihrauch TR
    Z Gastroenterol; 1988 Apr; 26(4):199-203. PubMed ID: 3149082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.